Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice.
Vincent Lambert,Julie Lecomte,Sylvain Hansen,Silvia Blacher,Maria-Luz Alvarez Gonzalez,Ingrid Struman,Nor Eddine Sounni,Eric Rozet,Pascal De Tullio,Jean-Michel Foidart,Jean-Marie Rakic,Agnès Noël +11 more
TLDR
This standardized protocol can be applied to transgenic mice and can include treatments with drugs, recombinant proteins, antibodies, adenoviruses and pre-microRNAs to aid in the search for new molecular regulators and the identification of novel targets for innovative treatments.Abstract:
The mouse model of laser-induced choroidal neovascularization (CNV) has been used extensively in studies of the exudative form of age-related macular degeneration (AMD). This experimental in vivo model relies on laser injury to perforate Bruch's membrane, resulting in subretinal blood vessel recruitment from the choroid. By recapitulating the main features of the exudative form of human AMD, this assay has served as the backbone for testing antiangiogenic therapies. This standardized protocol can be applied to transgenic mice and can include treatments with drugs, recombinant proteins, antibodies, adenoviruses and pre-microRNAs to aid in the search for new molecular regulators and the identification of novel targets for innovative treatments. This robust assay requires 7-14 d to complete, depending on the treatment applied and whether immunostaining is performed. This protocol includes details of how to induce CNV, including laser induction, lesion excision, processing and different approaches to quantify neoformed vasculature.read more
Citations
More filters
Journal ArticleDOI
Intravitreal injection of EV11, a novel aryl ketone amide, inhibits choroidal neovascularization via AKT/ERK1/2 pathway.
TL;DR: In this article , a novel derivative from Sorafenib, called EV11, was used to inhibit the formation of choroidal neovascularization (CNV) in mice.
Journal ArticleDOI
CRISPR/Cas9 mediated specific ablation of vegfa in retinal pigment epithelium efficiently regresses choroidal neovascularization
TL;DR: In this paper , a retinal pigment epithelium (RPE)-specific CRISPR/Cas9 system was developed to operate only in RPE by expressing Cas9 under the RPE-specific vitelliform macular dystrophy 2 promoter (pVMD2).
Journal ArticleDOI
JP1, a polypeptide specifically targeting integrin αVβ3, ameliorates choroidal neovascularization and diabetic retinopathy in mice
TL;DR: JP1 can be used to design novel CNV-targeting therapeutic agents that may replace current invasive intraocular injections, and it is concluded that JP1 could penetrate the blood-retinal barrier to target CNV lesion.
Journal ArticleDOI
Fiji-Assisted Automatic Quantitative Volumetric Analysis of Choroidal Neovascularization in a Laser-Induced Choroidal Neovascularization Mouse Model
TL;DR: Fiji-assisted automatic quantitative volumetric quantification of choroidal neovascularization (CNV) was used to detect experimental outliers in laser-induced CNV genesis and provided accurate and precise measurements of total areas of CNV as discussed by the authors .
Journal ArticleDOI
Clearance of lipid droplets by chimeric autophagy-tethering compound ameliorates the age-related macular degeneration phenotype in mice lacking APOE.
TL;DR: In this paper , the authors showed that LD accumulation was a trigger for the onset of AMD and provided entry points for the treatment of the initial insult of AMD by degrading LDs.
References
More filters
Journal ArticleDOI
Global data on visual impairment in the year 2002
Serge Resnikoff,Donatella Pascolini,Daniel Etya'ale,Ivo Kocur,Ramachandra Pararajasegaram,Gopal P. Pokharel,Silvio P Mariotti +6 more
TL;DR: Estimates from data on low vision and blindness as defined in the International statistical classification of diseases, injuries and causes of death, 10th revision show cataract remains the leading cause of visual impairment in all regions of the world, except in the most developed countries.
Journal ArticleDOI
Prevalence of age-related macular degeneration in the United States.
David S. Friedman,O'Colmain Bj,Beatriz Munoz,Sandra C. Tomany,Catherine A. McCarty,de Jong Pt,de Jong Pt,de Jong Pt,Barbara Nemesure,Paul Mitchell,Paul Mitchell,John H. Kempen +11 more
TL;DR: In this article, the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race/ethnicity, and gender was estimated.
Journal ArticleDOI
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S. Heier,David M. Brown,Victor Chong,Jean-François Korobelnik,Peter K. Kaiser,Quan Dong Nguyen,Bernd Kirchhof,Allen C. Ho,Yuichiro Ogura,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Georg Groetzbach,Bernd Sommerauer,Rupert Sandbrink,Rupert Sandbrink,Christian Simader,Ursula Schmidt-Erfurth +20 more
TL;DR: It is demonstrated that aflibercept is an effective treatment for AMD, with the every-2-month regimen offering the potential to reduce the risk from monthly intravitreal injections and the burden of monthly monitoring.
Prevalence of agerelated macular degeneration in the united states
TL;DR: Age-related macular degeneration was far more prevalent among white than among black persons, and the number of persons having AMD will increase by 50% to 2.95 million in 2020.